Dogwood Therapeutics, Inc. Market Cap ($30.92 Million)
Market Cap & Net Worth: Dogwood Therapeutics, Inc. (DWTX)
Dogwood Therapeutics, Inc. market cap. Dogwood Therapeutics, Inc. (NASDAQ:DWTX) has a market capitalization of $30.92 Million ($30.92 Million) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23442 globally and #5112 in its home market, demonstrating a -6.31% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Dogwood Therapeutics, Inc.'s stock price $1.04 by its total outstanding shares 29727866 (29.73 Million). Also see DWTX operating cash flow for how efficiently the company converts equity into cash flow.
Dogwood Therapeutics, Inc. Market Cap History (2020–2026)
Dogwood Therapeutics, Inc. market cap history from 2020 to 2026. Data shows change from $223.26 Million to $30.92 Million (-37.63% CAGR). Check Dogwood Therapeutics, Inc. (DWTX) share price today for real-time trading data and today's change.
Index Memberships
Dogwood Therapeutics, Inc. is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.61 Trillion | 0.00% | #658 of 976 |
Weight: Dogwood Therapeutics, Inc.'s market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Dogwood Therapeutics, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Dogwood Therapeutics, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Dogwood Therapeutics, Inc. (DWTX) net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of DWTX by Market Capitalization
Companies near Dogwood Therapeutics, Inc. in the global market cap rankings as of November 5, 2026. Also see Dogwood Therapeutics, Inc. (DWTX) total assets for a full breakdown of the balance sheet.
Key companies related to Dogwood Therapeutics, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #368 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #414 globally with a market cap of $68.22 Billion USD ( AU$96.41 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $530.76 |
| #368 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $973.36 |
| #414 | CSL Ltd | AU:CSL | $68.22 Billion | AU$198.72 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $228.44 |
Market Capitalization of Dogwood Therapeutics, Inc. (2020–2026)
Market capitalization of Dogwood Therapeutics, Inc. from 2020 to today. Between 2020 and today, Dogwood Therapeutics, Inc.'s market cap moved from $223.26 Million to $ 30.92 Million, with a yearly change of -37.63%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $30.92 Million | -75.00% |
| 2025 | $123.67 Million | +67.07% |
| 2024 | $74.02 Million | -82.68% |
| 2023 | $427.34 Million | +143.64% |
| 2022 | $175.39 Million | -95.39% |
| 2021 | $3.80 Billion | +1602.73% |
| 2020 | $223.26 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 4th, 2026 the market cap of Dogwood Therapeutics, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $30.92 Million USD |
| MoneyControl | $30.92 Million USD |
| MarketWatch | $30.92 Million USD |
| marketcap.company | $30.92 Million USD |
| Reuters | $30.92 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a fixed dose combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-… Read more